HR Execs on the Move

Mirna Therapeutics

www.mirnarx.com

 
Mirna Therapeutics, Inc. (Mirna) is a biotechnology research and development company focused on miRNA-directed oncology therapies. Featuring world-class research capabilities, a strong understanding of miRNA and cancer biology, and a broad IP portfolio, Mirna Therapeutics is well-positioned to capitalize on the emerging field of miRNA-based therapeutics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.mirnarx.com
  • 2150 Woodward St. Suite 100
    Austin, TX USA 78744
  • Phone: 512.901.0900

Executives

Name Title Contact Details

Similar Companies

NaturalNano Inc

NaturalNano Inc is a Pittsford, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Presbia

Presbia is a medical device company focused on the development of the presbyopia-correcting Presbia Flexivue Microlens™ – an innovative solution for the common age-related loss of the ability to read or focus on near objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.

Health Insight

Health Insight is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body`s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.

www.velosbio.com

VelosBio, Inc. operates as a biotechnology firm specializing in oncology.